NightHawk Biosciences (NYSE:NHWK – Get Free Report) released its earnings results on Monday. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), reports. The company had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $1.60 million. NightHawk Biosciences had a negative return on […]
NightHawk Biosciences (NYSE:NHWK – Get Free Report) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.08), reports. The firm had revenue of $0.66 million for the quarter, compared to analysts’ expectations of $0.90 million. NightHawk Biosciences had […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) and NightHawk Biosciences (NYSE:NHWK – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Valuation and Earnings This table compares Arcturus Therapeutics and […]
The SEZ6-targeted antibody-drug conjugate ABBV-011, when administered at 1 mg/kg every 3 weeks, was found to be well tolerated and to demonstrate early efficacy in patients with relapsed or refractory small cell lung cancer.